Travel writer takes an unexpected cancer journey
After years of guiding others on their travels, Rick Steves, a travel writer and television host based in Edmonds, Wash., took an unexpected detour after getting diagnosed with prostate cancer.
Related Articles
FDA Approves Remestemcel-L in Pediatric SR-aGVHD
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
Are Medications to Prevent Breast Cancer Right for You?
If you’re worried about your risk for breast cancer, you’re not alone. That’s especially true if you have a family history of the disease. But…
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Moving the Needle in ER-Positive / HER2-Negative MBC
Join us for this social media event on treating estrogen receptor (ER)-positive / HER2-negative metastatic breast cancer designed to encourage the exchange o…
MD Anderson Research Highlights for December 18, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to…
Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia & AACR
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
ASH 2024: Multiple Myeloma Studies May Change Practice
Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, according to experts.
DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.